Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products. The company operates in two divisions, Global Pharmaceuticals and Impax Pharmaceuticals. The company has a P/E ratio of 24.6, above the average drugs industry P/E ratio of 24.3 and above the S&P 500 P/E ratio of 17.7. Impax has a market cap of $1.34 billion and is part of the